• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Type 2 Asthma Learning Hub
    • Atopic Dermatitis Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • Prurigo Nodularis Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region

Educational Resources

Categories
Dermatology: 
  • Atopic dermatitis
  • Chronic spontaneous urticaria
  • Prurigo nodularis
Gastroenterology: 
  • Eosinophilic esophagitis
Pulmonology: 
  • Asthma
  • Chronic obstructive pulmonary disease
  • IL-33
Rhinology: 
  • Chronic rhinosinusitis with nasal polyps
Filters
Topic: 
  • Burden of disease
  • Pathophysiology
  • Guidelines and recommendations
  • Clinical management
  • Co-existing type 2 inflammatory diseases
Format: 
  • Expert Video
  • Podcast
  • Slide presentation
  • Infographic
  • Video animation
  • Interactivity
Length: 
  • Short (<5 minutes)
  • Medium (5-15 minutes)
  • Long (> 15 minutes)
Sort by: Newest
  • Newest
  • Oldest
  • A-Z
  • Z-A
Itch in Prurigo Nodularis
Dermatology
5 min
expert video

Itch in Prurigo Nodularis

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases
Type 2 Inflammation
4 min
expert video

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers
Type 2 Inflammation
2 min
expert video

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?
Type 2 Inflammation
4 min
expert video

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation
Type 2 Inflammation
3 min
expert video

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages
Pulmonology
21 min
Podcast

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact
Pulmonology
21 min
Podcast

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
3 min
expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
5 min
expert video

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
4 min
expert video

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
Dermatology
4 min
expert video

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

    1234
    ...
    31